A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
AstraZeneca & Daiichi Sankyo’s Datroway granted Priority Review in US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy: Cambridge ...
AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) has been accepted and granted ...
Kazia Therapeutics Ltd. has announced promising preclinical and translational data supporting the development of NDL-2, a ...
Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.
Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.
Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
MedPage Today on MSN
Novel treatments for gastric cancer
Immunotherapy, targeted treatments, HIPEC, and new delivery options ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
The company plans to begin enrolling the trial next quarter across eight US sites to test the vaccine as a monotherapy and in combination with Keytruda.
VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results